Roche Holding AG

Roche’s new oral MS drug, Fenebrutinib, cuts disability progression and preserves arm function with a safety profile similar to Ocrevus, while the company supports early‑career researchers and maintains a stable market outlook.

Roche Holding AG’s AI‑driven R&D, diversified pipeline and emerging market growth face patent cliffs, regulatory shifts and investor uncertainty – a nuanced analysis for informed investors.

Goldman Sachs lifts Roche Holding to neutral, citing stronger diagnostics-driven pricing and solid balance sheet amid looming patent cliffs – a fresh outlook for investors.

Roche Holding AG’s bold obesity and YL201 moves spotlight a rare diagnostics‑therapeutics synergy—explore how this could reshape its revenue and risk profile.

Roche’s share rise after U.S. drug‑price settlement shows investors believe tariff exemptions will offset revenue loss while keeping Genentech biologics safe, effective, and more affordable.

Roche’s share hits a 12‑month high after JPMorgan upgrades it to neutral—backed by new EU approval for Gazyva in lupus nephritis and a promising Lunsumio/Lenalidomide combo for lymphoma, signaling strong regulatory momentum and investment confidence.

Roche’s latest gains stem from Gazyva’s lupus nephritis launch, EU approval for subcutaneous Lunsumio, and a rapid‑testing partnership, boosting investor confidence in its diversified therapeutic and diagnostic pipeline.

Roche Holding AG has announced several strategic milestones, including positive clinical trial results, licensing agreements, and regulatory approvals, positioning the company for long-term growth in the competitive pharmaceutical and biotechnology …

Roche Holding AG has achieved significant market access and development milestones, including regulatory approvals for several new cancer treatments, a proposed reduction in value-added tax in Germany, and a robust pipeline of combination therapies,…

Roche Holding AG’s recent regulatory gains and strategic moves, including the approval of its follicular lymphoma therapy Lunsumio and the acquisition of 89bio, are expected to drive growth, but the company must navigate a complex regulatory environ…